drugset / Trial / NCT04070495
A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the effects of CYP3A4/5 inhibitor or inducer on the pharmacokinetics of KW-6356 when CYP3A4/5 inhibitor or inducer is orally administered to healthy Japanese men for 7 days.
Timeline
- Start
- 2019-08-27
- Primary completion
- 2019-11-19
- Completion
- 2019-11-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clarithromycin | Small molecule | 400 mg | Oral |
| Subject | Rifampin | Small molecule | 600 mg | Oral |
| Subject | SIPAGLADENANT | Small molecule | — | Oral |